RUNX1 (Acetyl Lys24) rabbit pAb

活动价:

¥680.00

市场价:¥880.00

一键复制产品信息
产品规格:
  • 50μL
  • 100μL
货号:

FAB2600346

  • 产品信息
  • 注意事项
  • 实验验证
  • 产品声明
  • 引用文献
  • 相关产品
  • 文件下载
商品描述
  • 靶点-Target

    RUNX1

  • 反应性

    Human,Mouse,Rat

  • 应用

    WB,ELISA

  • 宿主物种-Host Species

    Rabbit

  • 同种型-Isotype

    IgG

  • 修饰-Modification

    Acetyl

  • MW(Observed)

    50kD

  • 推荐稀释比

    WB 1:1000-2000;ELISA 1:5000-20000

  • 组成

    Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

  • 纯化工艺

    The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.

  • 储存

    -15°C to -25°C/1 year(Do not lower than -25°C)

  • 浓度

    1 mg/ml

  • 克隆性

    Polyclonal

  • 免疫原

    Synthesized peptide derived from human RUNX1 (Acetyl Lys24)

  • 特异性

    This antibody detects endogenous levels of Human,Mouse,Rat RUNX1 (Acetyl Lys24)

  • 基因名称

    RUNX1 AML1 CBFA2

  • 蛋白名称

    RUNX1 (Acetyl Lys24)

  • 别名

    Runt-related transcription factor 1;Acute myeloid leukemia 1 protein;Core-binding factor subunit alpha-2;CBF-alpha-2;Oncogene AML-1;Polyomavirus enhancer-binding protein 2 alpha B subunit;PEA2-alpha B;PEBP2-alpha B;SL3-3 enhancer factor 1 alpha B subunit;SL3/AKV core-binding factor alpha B subunit;

  • Organism-1

    Human

  • 基因ID-1

    861

  • SwissProt-1

    Q01196

  • Organism-2

    Mouse

  • 基因ID-2

    12394

  • SwissProt-2

    Q03347

  • Organism-3

    Rat

  • 基因ID-3

    50662

  • SwissProt-3

    Q63046

  • 背景

    alternative products:Additional isoforms seem to exist,caution:The fusion of AML1 with EAP in T-MDS induces a change of reading frame in the latter resulting in 17 AA unrelated to those of EAP.,disease:A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelogenous leukemia (CML). Translocation t(3;21)(q26;q22) with EAP, MSD1 or EVI1.,disease:A chromosomal aberration involving RUNX1/AML1 is a cause of chronic myelomonocytic leukemia. Inversion inv(21)(q21;q22) with USP16.,disease:A chromosomal aberration involving RUNX1/AML1 is a cause of M2 type acute myeloid leukemia (AML-M2). Translocation t(8;21)(q22;q22) with RUNX1T1/MTG8/ETO.,disease:A chromosomal aberration involving RUNX1/AML1 is a cause of therapy-related myelodysplastic syndrome (T-MDS). Translocation t(3;21)(q26;q22) with EAP, MSD1 or EVI1.,disease:A chromosomal aberration involving RUNX1/AML1 is found in childhood acute lymphoblastic leukemia (ALL). Translocation t(12;21)(p13;q22) with TEL. The translocation fuses the 3'-end of TEL to the alternate 5'-exon of AML-1H.,disease:A chromosomal aberration involving RUNX1/AML1 is found in therapy-related myeloid malignancies. Translocation t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.,disease:Defects in RUNX1 are the cause of familial platelet disorder with associated myeloid malignancy (FPDMM) [MIM:601399]. FPDMM is an autosomal dominant disease characterized by qualitative and quantitative platelet defects, and propensity to develop acute myelogenous leukemia.,domain:A proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes.,function:CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits MYST4-dependent transcriptional activation.,PTM:Methylated.,PTM:Phosphorylated in its C-terminus upon IL-6 treatment. Phosphorylation enhances interaction with MYST3.,similarity:Contains 1 Runt domain.,subunit:Heterodimer with CBFB. RUNX1 binds DNA as a monomer and through the Runt domain. DNA-binding is increased by heterodimerization. Isoform AML-1L can neither bind DNA nor heterodimerize. Interacts with TLE1 and THOC4. Interacts with ELF1, ELF2 and SPI1. Interacts via its Runt domain with the ELF4 N-terminal region. Interaction with ELF2 isoform 2 (NERF-1a) may act to repress RUNX1-mediated transactivation. Interacts with MYST3 and MYST4. Interacts with SUV39H1, leading to abrogate the transactivating and DNA-binding properties of RUNX1.,tissue specificity:Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood.,

  • 细胞定位

    Nucleus.